The European Medicines Agency (EMA) has started reviewing the preliminary data on two Eli Lilly treatments for Covid-19, writes the Danish Medicines Agency in a press announcement.
This will be in the form of a rolling review of the antibody bamlanivimab and a bamlanivimab-etesevimab combination.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.